Skip to main content
. Author manuscript; available in PMC: 2020 May 7.
Published in final edited form as: Ann Intern Med. 2019 Apr 9;170(9):594–603. doi: 10.7326/M18-1715

Figure 1. Flow diagram of PREVAIL study participants.

Figure 1.

DOT = directly observed therapy; GT = group treatment; HCV = hepatitis C virus; OAT = opioid agonist therapy; PREVAIL = Prevent Resistance Eliminate Virus and Improve Life; SIT = self-administered individual treatment.

* Three SIT participants with no available blister pack adherence data were not included in the analysis of the primary adherence outcome.